Loading clinical trials...
Loading clinical trials...
To determine if ditiocarb sodium (sodium diethyldithiocarbamate; DTC) restores immune and host defense function; if DTC ameliorates the AIDS related complex (ARC) symptoms in patients with AIDS and ARC; if DTC prevents progression from ARC to AIDS or progression of AIDS; and if DTC prolongs survival in AIDS.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Univ of Arizona / Arizona Cancer Ctr
Tucson, Arizona, United States
USC School of Medicine / Norris Cancer Hosp
Los Angeles, California, United States
San Francisco AIDS Clinic / San Francisco Gen Hosp
San Francisco, California, United States
Portion Med Group
Sherman Oaks, California, United States
Florida Keys Memorial Hosp
Key West, Florida, United States
SUNY / Health Sciences Ctr at Brooklyn
Brooklyn, New York, United States
Duke Univ Med Ctr
Durham, North Carolina, United States
Dr Gary Brewton
Houston, Texas, United States
Last Updated
June 24, 2005
Ditiocarb sodium
DRUG
Lead Sponsor
Merieux Institute
NCT04142047
NCT06694805
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07428330